Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

K. Van der Geest; O. Vermeulen; E. Brouwer; R.H.J.A. Slart; M. Sandovici; A. Rutgers; T.J. Hiltermann; B. Hiddinga; S. Oosting; M. Jalving; A. De Heij; D. Knapen; G. Hospers

doi:10.1136/annrheumdis-2024-eular.2395

Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

K. Van der Geest, O. Vermeulen, E. Brouwer, R.H.J.A. Slart, M. Sandovici, A. Rutgers, T.J. Hiltermann, B. Hiddinga, S. Oosting, M. Jalving, A. De Heij, D. Knapen, G. Hospers

Biomedical Photonic Imaging

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1090-1091
Journal	Annals of the Rheumatic Diseases
Volume	83
Issue number	Suppl. 1
DOIs	https://doi.org/10.1136/annrheumdis-2024-eular.2395
Publication status	Published - 1 Jun 2024
Event	EULAR Annual European Congress of Rheumatology 2024 - Vienna, Austria Duration: 12 Jun 2024 → 15 Jun 2024

Keywords

NLA

Access to Document

10.1136/annrheumdis-2024-eular.2395

Cite this

Van der Geest, K., Vermeulen, O., Brouwer, E., Slart, R. H. J. A., Sandovici, M., Rutgers, A., Hiltermann, T. J., Hiddinga, B., Oosting, S., Jalving, M., De Heij, A., Knapen, D., & Hospers, G. (2024). Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Annals of the Rheumatic Diseases, 83(Suppl. 1), 1090-1091. https://doi.org/10.1136/annrheumdis-2024-eular.2395

@article{a1667fbf3bbe4e02ba042e115a870cf9,

title = "Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement",

keywords = "NLA",

author = "\{Van der Geest\}, K. and O. Vermeulen and E. Brouwer and R.H.J.A. Slart and M. Sandovici and A. Rutgers and T.J. Hiltermann and B. Hiddinga and S. Oosting and M. Jalving and \{De Heij\}, A. and D. Knapen and G. Hospers",

year = "2024",

month = jun,

day = "1",

doi = "10.1136/annrheumdis-2024-eular.2395",

language = "English",

volume = "83",

pages = "1090--1091",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ",

number = "Suppl. 1",

note = "EULAR Annual European Congress of Rheumatology 2024, EULAR ; Conference date: 12-06-2024 Through 15-06-2024",

}

Van der Geest, K, Vermeulen, O, Brouwer, E, Slart, RHJA, Sandovici, M, Rutgers, A, Hiltermann, TJ, Hiddinga, B, Oosting, S, Jalving, M, De Heij, A, Knapen, D & Hospers, G 2024, 'Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement', Annals of the Rheumatic Diseases, vol. 83, no. Suppl. 1, pp. 1090-1091. https://doi.org/10.1136/annrheumdis-2024-eular.2395

Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. / Van der Geest, K.; Vermeulen, O.; Brouwer, E. et al.
In: Annals of the Rheumatic Diseases, Vol. 83, No. Suppl. 1, 01.06.2024, p. 1090-1091.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Pos 1429 Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

AU - Van der Geest, K.

AU - Vermeulen, O.

AU - Brouwer, E.

AU - Slart, R.H.J.A.

AU - Sandovici, M.

AU - Rutgers, A.

AU - Hiltermann, T.J.

AU - Hiddinga, B.

AU - Oosting, S.

AU - Jalving, M.

AU - De Heij, A.

AU - Knapen, D.

AU - Hospers, G.

PY - 2024/6/1

Y1 - 2024/6/1

KW - NLA

U2 - 10.1136/annrheumdis-2024-eular.2395

DO - 10.1136/annrheumdis-2024-eular.2395

M3 - Article

SN - 0003-4967

VL - 83

SP - 1090

EP - 1091

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl. 1

T2 - EULAR Annual European Congress of Rheumatology 2024

Y2 - 12 June 2024 through 15 June 2024

ER -